MaxCyte, Inc. Notice of Maiden Full Year Results (8036W)
April 29 2016 - 4:00AM
UK Regulatory
TIDMMXCT
RNS Number : 8036W
MaxCyte, Inc.
29 April 2016
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Maiden Full Year Results
Maryland, USA - 29 April 2016: MaxCyte (LSE: MXCT), the
developer and supplier of cell engineering technology to
biotechnology and pharmaceutical firms engaged in cell therapy,
drug discovery and development, biomanufacturing, gene editing and
immuno-oncology, will be announcing its maiden full year results
for the year ended 31 December 2015 on Tuesday 10 May 2016.
Doug Doerfler, Chief Executive Officer, will host a presentation
and live conference call for analysts at 11.00am BST on the day of
the results at the offices of Consilum Strategic Communications, 41
Lothbury, London, EC2R 7HG.
For further information please contact:
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Fabien Holler
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
About MaxCyte
MaxCyte is an established and revenue generating US-based
developer and supplier of cell engineering technology to
biotechnology and pharmaceutical firms engaged in cell therapy,
drug discovery and development, biomanufacturing, gene editing and
immuno-oncology. The Company's patented flow electroporation
technology enables its products to deliver fast, reliable and
scalable cell engineering to drive the research and clinical
development of a new generation of cell-based medicines.
MaxCyte's high performance platform allows transfection with any
molecule or multiple molecules and is compatible with nearly all
cell types, including hard-to-transfect human primary cells. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large scale, commercial
and clinical grade cell engineering in a non-viral system and with
low toxicity concerns. The Company's cell engineering technology
platform is CE-marked and FDA-accredited, providing MaxCyte's
customers with an established regulatory path.
MaxCyte is developing CARMA, its proprietary platform in
immuno-oncology, to deliver a validated non-viral approach to CAR
therapies in a number of cancer indications, including solid
tumors.
For more information visit http://www.maxcyte.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDMGZDNLVGVZG
(END) Dow Jones Newswires
April 29, 2016 04:00 ET (08:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024